Payment overview · 2025
General Payments
$699.02
25 reported records · 12 companies
Healthcare provider profile · identity verified
Melissa A Nihiser, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · ZEPHYRHILLS, FL · NPI 1033458831
Verified facts
What the public records show
CMS Open Payments records show Melissa A Nihiser, ARNP received $699.02 in general payments during 2025 across 25 reported records.
CVRx, Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CVRx, Inc. | Unresolved — no canonical attribution shown | $158.15 | 22.6% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $120.52 | 17.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.18 | 15.6% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.36 | 11.1% | 3 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $43.38 | 6.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $36.86 | 5.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.73 | 4.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.35 | 4.6% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.10 | 4.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.14 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.26 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.99 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $699.02 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $158.15 | 4 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $120.52 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $91.32 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.36 | 3 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $43.38 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $36.86 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 418 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 127 |
| Simvastatin | Simvastatin | 332 | 101 |
| Omeprazole | Omeprazole | 236 | 78 |
| Lisinopril | Lisinopril | 221 | 74 |
| Metformin Hcl | Metformin Hcl | 211 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 71 |
| Losartan Potassium | Losartan Potassium | 177 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 57 |
| Methylprednisolone | Methylprednisolone | 159 | 132 |
| Furosemide | Furosemide | 149 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 43 |
| Tramadol Hcl | Tramadol Hcl | 114 | 29 |
| Alprazolam | Alprazolam | 106 | 22 |
| Gabapentin | Gabapentin | 96 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 34 |
| Allopurinol | Allopurinol | 93 | 28 |
| Trazodone Hcl | Trazodone Hcl | 93 | 31 |
| Potassium Chloride | Potassium Chloride | 88 | 35 |
| Ozempic | Semaglutide | 83 | 21 |
| Montelukast Sodium | Montelukast Sodium | 81 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 28 |
| Glimepiride | Glimepiride | 70 | 21 |
| Meloxicam | Meloxicam | 70 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 39 |
| Buspirone Hcl | Buspirone Hcl | 65 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 37 |
| Azithromycin | Azithromycin | 60 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 30 |
| Ezetimibe | Ezetimibe | 57 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 47 |
| Carvedilol | Carvedilol | 54 | 17 |
| Famotidine | Famotidine | 54 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 47 |
| Prednisone | Prednisone | 53 | 50 |
| Valacyclovir | Valacyclovir Hcl | 52 | 18 |
| Lovastatin | Lovastatin | 50 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 48 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 42 |
| Glipizide | Glipizide | 47 | 12 |
| Januvia | Sitagliptin Phosphate | 47 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 17 |
| Rybelsus | Semaglutide | 47 | 15 |
| Sertraline Hcl | Sertraline Hcl | 47 | 20 |
| Alendronate Sodium | Alendronate Sodium | 45 | 18 |
| Spironolactone | Spironolactone | 44 | 14 |
| Fenofibrate | Fenofibrate | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 14 |
| Synthroid | Levothyroxine Sodium | 40 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | 11 |
| Eliquis | Apixaban | 33 | 14 |
| Glipizide Er | Glipizide | 33 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 11 |
| Atenolol | Atenolol | 31 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 12 |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Ondansetron Odt | Ondansetron | 24 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 16 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Topiramate | Topiramate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Ramipril | Ramipril | 15 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $699.02 · 25 records | CVRx, Inc. | AREXVY, AURYON LASER SYSTEM 100-120 VAC, Barostim Neo System, Cologuard Collection Kit, JARDIANCE, KEVZARA, Kerendia, OPSUMIT, OTEZLA, Ozempic, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error